Image-guided cardiovascular procedures use advanced, real-time imaging like fluoroscopy, echocardiography, and MRI to guide minimally invasive treatments, and recovery time. These methods facilitate faster recovery and improved patient outcomes by allowing real-time adjustments and minimizing invasive surgical trauma.
The CE Mark was granted under the European Medical Device Regulation (MDR), which confirms compliance with applicable EU safety, health, and environmental protection standards.
"The launch of ACIST Pro™ is an important step in our ongoing effort to advance precision imaging across specialties," said Dr. Fulvio Renoldi Bracco, CEO of Bracco Imaging. "By thoughtfully evolving a trusted platform, we are responding to the real-world needs of today's interventional teams. This milestone reflects our commitment to delivering practical, forward-looking solutions that support quality, safety, and sustainability in diagnostic imaging."
"Building on the trusted ACIST CVi® system, ACIST Pro™ is our next-generation solution, enhancing precision and efficiency in the cardiac catheterization laboratory. With its European launch, we are proud to bring this advanced technology to clinicians and continue our commitment to innovation in interventional imaging," said Brad Fox, CEO of ACIST Medical Systems.
With this European launch, Bracco and ACIST Medical Systems continue to advance their shared mission of delivering practical solutions that support precision, safety, and performance across interventional cardiology, radiology, and vascular care.
ACIST Medical Systems, Inc., a Bracco Group company and a global leader in advanced contrast management technologies, today announced the launch in selected markets in Europe of the ACIST Pro™ Diagnostic System, a next-generation variable-rate contrast management solution designed to advance precision, safety and efficiency in image-guided cardiovascular procedures.










.jpeg)